Literature DB >> 6627823

Vancomycin kinetics during continuous ambulatory peritoneal dialysis.

C M Bunke, G R Aronoff, M E Brier, R S Sloan, F C Luft.   

Abstract

To establish therapeutic guidelines for vancomycin usage in patients receiving continuous ambulatory peritoneal dialysis (CAPD), we studied single-dose kinetics of vancomycin in CAPD patients. Vancomycin was studied after a 10-mg/kg dose was given intravenously (VAN-IV) or intraperitoneally (VAN-IP). VAN-IV provided a plasma concentration above 10 mg/l at 12 hr, with a t 1/2 of 81 hr. When VAN-IP was given, 65% was absorbed; peak plasma concentrations were only 6.3 mg/l, and t 1/2 was 66 hr. CAPD accounted for only 15% to 17% of total body clearance in both groups. The kinetic principle of superposition was used to predict plasma concentrations after repeated VAN-IP doses. A model with once-a-day dosing predicted that a loading dose of 30 mg/kg followed by 7 mg/kg would achieve steady-state plasma concentrations of 11 to 14.8 mg/l. Another model with vancomycin in each exchange predicted that a loading dose of 30 mg/kg followed by 1.5 mg/kg would provide plasma concentrations in excess of 10 mg/l at 180 hr. These data should be useful in vancomycin treatment of CAPD patients who have nonperitoneal gram-positive bacterial infections, as well as those who have peritonitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627823     DOI: 10.1038/clpt.1983.225

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  A clinical view of vancomycin in 1990.

Authors:  W T Siebert
Journal:  Tex Heart Inst J       Date:  1990

2.  Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis.

Authors:  G R Bailie; G Eisele; R A Venezia; D Yocum; A Hollister
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 3.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

4.  Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis.

Authors:  D Neal; G R Bailie
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

5.  Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.

Authors:  G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva; M Bonati
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

Review 7.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

8.  Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R D Blevins; C E Halstenson; N G Salem; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

10.  Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer.

Authors:  R C Evans; C J Holmes
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.